Amgen Inc. (AMGN )

Currency in USD Disclaimer
$325.09 +$0.47 (0.14%)
Closed 10/15/2024
$324.03
$327.33
$249.7
$346.85

Company brief: AMGEN INC. (AMGN )


Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AMGN Corporation News

Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

October 15, 2024 at 7:01 pm ET

zacks.com -- Amgen (AMGN) closed at $325.09 in the latest trading session, marking a +0.14% move from the prior day....

AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024

October 15, 2024 at 8:00 am ET

prnewswire.com -- MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ Patients First and Only Phase 3 Placebo-Controlled gMG Trial for a Biologic That Tapered Cortico...

Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.

October 14, 2024 at 10:15 am ET

barrons.com -- The pharma company has a lot riding on its experimental obesity drug MariTide....

Amgen's stock falls as analyst warns that hype around obesity drug is baked in

October 14, 2024 at 10:02 am ET

marketwatch.com -- Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech's drug pipeline....

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

October 14, 2024 at 10:00 am ET

zacks.com -- Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock....

Income Statement